Deccan Health Care
- Market cap
- ₹ 29 Cr.
- P/E
- 11.7x
- P/B
- 0.29x
- 52-week range
- 6.65 – 18.4
- ROE
- 2%
- ROCE
- 3.1%
- Dividend yield
- 0%
- Debt / equity
- 0.04
- Sector
- Healthcare Services
- Industry
- Healthcare Service Provider
- Listed on
- BSE
About
Deccan Health Care Limited is an India-based company, which is engaged in the business of manufacturing of nutraceuticals. The Company’s robust portfolio of 1500 market-ready products include 73 pioneering offerings and over 200 differentiated products. This includes several product classifications, such as immune, cardiovascular, digestive, personal care, weight management and other general health products. Its key categories of nutraceuticals, including vitamins and minerals, probiotics, proteins and peptides, omega fatty acids and others. Its nutraceuticals are available in several forms, including capsules, tablets, soft gels, powders, liquids, and gummies. They find applications in functional foods, functional beverages, dietary supplements and personal care products.
Quick check
The five things to look at first. Open one for more.
Compared with its industry
Healthcare Service Provider: 36 companies →Deccan Health Care against the typical company in its industry. The rank is out of the companies that report each figure; green means the better quarter of the pack, red the worse quarter.
- Valuation (P/E)11.7 against a typical 21: cheaper than most peers (1st = cheapest).6th of 34
- Sales growth+1.8% against a typical +19.1% from a year earlier.26th of 31
- Profit growth+19% against a typical +25.2% from a year earlier.14th of 24
- Share price, 3 months−5.1% against a typical −7.7%.13th of 33
- Size₹ 28.9 Cr. market value against a typical ₹ 83 Cr. (1st = largest).23rd of 34
Financials
Consolidated figures in ₹ crore.
| ₹ Cr. | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 17 | 15 | 16 | 15 | 19 | 20 | 21 | 21 | 24 | 23 | 20 | 22 |
| Expenses | 16 | 14 | 15 | 14 | 18 | 20 | 20 | 21 | 23 | 21 | 19 | 21 |
| Operating Profit | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 1 |
| OPM % | 6% | 8.1% | 4.1% | 5.8% | 6% | 2.9% | 3% | 3.4% | 7% | 7.3% | 3.8% | 3.8% |
| Other Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Tax % | 25.4% | 32.9% | 58.6% | 26.5% | 25% | 23.8% | 44% | 30% | 26.2% | 26.4% | 8% | 25% |
| Net Profit | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| EPS in Rs | 0.31 | 0.27 | 0.06 | 0.18 | 0.26 | 0.07 | 0.06 | 0.08 | 0.36 | 0.38 | 0.09 | 0.1 |
Growth and returns
Compounded yearly rates over each period.
- 10 Years
- 19%
- 5 Years
- 21%
- 3 Years
- 26%
- TTM
- 10%
- 10 Years
- −5%
- 5 Years
- 42%
- 3 Years
- 79%
- TTM
- 122%
- 10 Years
- —
- 5 Years
- −13%
- 3 Years
- −20%
- TTM
- —
- 10 Years
- 8%
- 5 Years
- 2%
- 3 Years
- 2%
- TTM
- —
P/E and EPS over time
Daily P/E and trailing 12-month EPS. EPS updates with each result.
Peers
Listed companies in the same business.
| Deccan Health Care | ₹ 12.40 | ₹ 29 Cr. | 11.7x | 0.3x | 2% | — |
| Sun Pharmaceutical Industries | ₹ 1,743.00 | ₹ 4,18,194 Cr. | 36.1x | 5.2x | — | 19.8% |
| Divi's Laboratories | ₹ 8,984.00 | ₹ 2,38,497 Cr. | 94x | 14.7x | — | 26.1% |
| Torrent Pharmaceuticals | ₹ 4,482.00 | ₹ 1,70,475 Cr. | 73.3x | 19.4x | — | 13.7% |
| Zydus Lifesciences | ₹ 1,127.85 | ₹ 1,12,503 Cr. | 21.5x | 4.3x | — | 15.7% |
| Cipla | ₹ 1,337.00 | ₹ 1,08,011 Cr. | 26.2x | 3.2x | — | 11.9% |
Management
- Minto Purshotam Gupta
- Chairman of the Board, Managing Director
- Tushar Mandal
- Chief Financial Officer
- Mohita Gupta
- Chief Operating Officer
- Shikha Das
- Compliance Officer, Company Secretary
- Meenakshi Gupta
- Additional Whole-Time Director
- Mohak Gupta
- Additional Whole time Director
- Rani Venkata Satya Umamaheswara Rao
- Whole Time Director
Prices are delayed and for information only. Nothing on this page is investment advice.